This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin [GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this study is to establish a recruitment database of individuals who have contacted the research staff in the department of dermatology expressing interest in participating in clinical research and requesting to be contacted if eligible to participate.

Normal kidney has the ability to increase its filtration rate in response to a stress such as a protein load. In chronic kidney disease, the existing kidney functional units(nephrons)may already be operating at their maximum operating capacity and may not have much reserve available to increase filtration in response to a stress. These individuals may have normal labs, blood pressure and filtration rate, but have a decreased reserve function to increase in response to stress. There are studies in adults that show that decrease renal reserve can be a predictor of disease progression but there are no studies in children to show that. We aim to prove that this is also true in the case of children.THIS STUDY IS ENROLLING BY INVITATION ONLY - The controls will be recruited from siblings of patients in other studies, for example, Multiomics Urine, Serum and Tissue Assessment of Nephrosis and Glomerulonephritis (in FINN clinic) IRB #26100, Chronic Kidney Disease in Children Study (CKiD) IRB#17114, CureGN: Cure Glomerulonephropathy Network Version 2.0, IRB# 2002385285 and from well child visits from pediatric clinics. They will be identified by physicians or PI and Co-PI. They may be approached on phone or in person if they are in a clinic or another study. Research procedures will occur in CCRC(Children's clinical research center) at Riley and research coordinators and staff will be collecting data and conducting the study procedures under the supervision of the PI and co-PI. Parents/legal guardians of children who will be approached for consent will be identified by the PI and Co-PI and research coordinators will obtain consent. The consent and study procedures will take place in a private area with the door closed.

The main objective of this clinical investigation is to assess the safety and feasibility of the Optilume DCB for treatment of ureteric strictures. Other objectives include characterizing the following through descriptive analysis: • Adverse event profile • Improvement in flank pain • Renal function changes • Improvement in hydronephrosis • Need for retreatment • Pharmacokinetics of paclitaxel in the blood and urineTHIS STUDY IS ENROLLING BY INVITATION ONLY - Patients seen for the treatment of ureteric stricture should be screened for study eligibility. The site may pre-screen potential subjects by reviewing medical records to identify the study population. Once identified, these subjects are approached to discuss the study and asked to participate.

SELECT LATE trial aims to evaluate if addition of endovascular thrombectomy to medical management in patients presenting with acute ischemic stroke and a proximal large vessel occlusion in the anterior circulation between 24 and 72 hours of stroke onset results in achieving better functional outcomes (measured using modified Rankin Scale Scores) at 90-day follow-up (± 15 days).THIS STUDY IS ENROLLING BY INVITATION ONLY 

This is a sequential multiple assignment randomized trial for adults (ages > 18) with a bipolar disorder type 1 diagnosis currently experiencing a depressive episode. It is a randomized pragmatic trial that will compare four commonly prescribed treatments for bipolar depression, which includes three FDA-approved medications (Cariprazine, Quetiapine and Lurasidone) and one antipsychotic/antidepressant combination (Aripiprazole/Escitalopram). THIS STUDY IS ENROLLING BY INVITATION ONLY - IU-affiliated investigators will identify subjects with bipolar depression and randomize them to one of four treatment options.